𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Multikinase inhibitor Sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL

✍ Scribed by Fadeev, R. S. ;Chekanov, A. V. ;Dolgikh, N. V. ;Akatov, V. S.

Book ID
119881537
Publisher
Biophysical Society of Japan
Year
2012
Tongue
English
Weight
191 KB
Volume
57
Category
Article
ISSN
1349-2942

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The histone deacetylase inhibitor, suber
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
✍ Lisa M. Butler; Vasilios Liapis; Stelios Bouralexis; Katie Welldon; Shelley Hay; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 958 KB

## Abstract While the apoptosis‐inducing ligand Apo2L/TRAIL is a promising new agent for the treatment of cancer, the sensitivity of cancer cells for induction of apoptosis by Apo2L/TRAIL varies considerably. Identification of agents that can be used in combination with Apo2L/TRAIL to enhance apopt